
IndraLab
Statements
Hydroxychloroquine inhibits Malaria. 13 / 13
2
|
6
5
eidos
"Current status of clinical trial studies on the interventions against COVID-19 across the world as of July 31 , 2020 ( Source : National Institute of Health , https://clinicaltrials.gov/ ) Accessed on Aug 1 , 2020 Hydroxychloroquine is FDA-approved to prevent and treat malaria , as well as to treat the autoimmune diseases rheumatoid arthritis and lupus [ 44-48 ] ."
| PMC
reach
"This was hydroxychloroquine, used to treat the symptoms of SLE and rheumatoid arthritis (RA) and to prevent and treat malaria, that reduced cellularity to 4.64 × 10 cells/mL in average (p = 0.0002), and FTY720, used to treat relapsing forms of multiple sclerosis, that reduced cellularity to 2.43 × 10 cells/mL in average (p < 0.0001)."
eidos
"Both chloroquine and hydroxychloroquine are used to prevent and treat malaria , being some of the antimalarial drugs of choice in areas where the disease is not resistant to them ( a recurrent problem in this disease ) ; they were preferred over quinine because of much less severe adverse effects , although at present there are many other even safer alternative drugs for the treatment of malaria ."
reach
"There should be close monitoring for adverse drug reactions and discontinuation of the drug if intolerable adverse reaction develops (http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae61004f-930d47598711a0d4cbf874a9.pdf)Hydroxychloroquine has been used for decades to prevent and treat malaria (it was first used during World War II) and is also effective as an anti-inflammatory and immunomodulatory agent for the management of various autoimmune rheumatic diseases, such as rheumatoid arthritis, Sjögren’s syndrome, systemic lupus erythematosus, and even sarcoidosis."
reach
"Whereas, hydroxychloroquine was first used to prevent and treat malaria and is currently used to treat rheumatoid arthritis, some symptoms of systemic lupus erythematosus, juvenile idiopathic arthritis, and other autoimmune diseases.Although ongoing clinical trials are testing the efficacy and safety of several treatments for COVID-19, including chloroquine and hydroxychloroquine, there is not yet credible evidence from clinical trials on the efficacy and safety of those agents in COVID-19."
reach
"However, another retrospective study demonstrated little effect of umifenovir on improving clinical consequences in non-ICU patients [201] , suggesting more trials for accessing the effects of umifenovir in COVID-19.Chloroquine (CQ) and hydroxychloroquine (HCQ) are used to prevent/treat malaria."